If you have been reading about c-Met receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3). 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. pp. 030001-1–030001-17 pp. 030001-18–030001-138, Table I. The NUBASE2016 table of nuclear and decay properties Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
=== Diabetes === RAGE plays a pivotal role in the pathogenesis of diabetes. RAGE, a multi-ligand receptor from the immunoglobulin superfamily, primarily binds to Advanced glycation end-products (AGEs) formed through the non-enzymatic glycation of proteins and lipids. In diabetes, hyperglycemia accelerates AGE formation, fostering a pro-inflammatory and pro-oxidative environment that worsens vascular damage and immune cell dysfunction. In both type 1 and type 2 diabetes, RAGE significantly contributes to microvascular and macrovascular complications. It is highly expressed in diabetic blood vessels, cardiomyocytes, podocytes, and immune cells, where it co-localizes with ligands such as AGEs, S100 proteins, and high-mobility group box 1 (HMGB1). This co-localization leads to chronic cellular stress and inflammation, which differs from the transient inflammatory responses associated with acute infections. RAGE activation contributes to complications such as diabetic nephropathy and retinopathy. Studies in diabetic mouse models suggest that blocking RAGE with soluble receptor forms (sRAGE) can mitigate these conditions by reducing mesangial sclerosis, basement membrane thickening, and endothelial damage. Additionally, RAGE's interaction with AGEs and S100 proteins accelerates atherosclerosis in diabetes, marked by increased lesion complexity, macrophage accumulation, and vascular inflammation.
There are debates over other potential causes such as nighttime drops in blood pressure, as well as the hypothesis that the optic disc's ability to regulate its blood flow may be compromised. Some researchers have even suggested that blockages in the veins could be responsible. One hypothesis suggests that the underlying cause may be a subtle decrease in blood flow to the optic nerve, which is enough to cause swelling of the nerve fibers but not severe enough to disrupt vision through tissue death and permanent damage to the optic nerve. When considering the possible causes for spontaneous NAION, the list includes other conditions like arteritic anterior ischemic optic neuropathy (associated with inflammation of arteries), optic neuritis (inflammation of the optic nerve), infiltrative and compressive types of optic neuropathy (where the optic nerve is invaded or pressed upon by abnormal substances or structures), diabetic papillopathy (swelling of the optic disc in diabetes), radiation-induced damage to the optic nerve, neuroretinitis (inflammation of the optic nerve and retina), and swelling of the optic disc linked with retinal diseases like central retinal vein occlusion.
"The IDO-like myoglobin is unexpectedly widely distributed among gastropodic molluscs, such as Sulculus, Nordotis, Battilus, Omphalius and Chlorostoma." The hemocyanin from arthropods and molluscs evolved from different ancestors, tyrosinase and insect storage proteins, respectively. They have different molecular weight and structure. However, the proteins both use copper binding sites to transport oxygen. The hexokinase, ribokinase, and galactokinase families of sugar kinases have similar enzymatic functions of sugar phosphorylation, but they evolved from three distinct nonhomologous families since they all have distinct three-dimensional folding and their conserved sequence patterns are strikingly different. Hemoglobins in jawed vertebrates and jawless fish evolved independently. The oxygen-binding hemoglobins of jawless fish evolved from an ancestor of cytoglobin which has no oxygen transport function and is expressed in fibroblast cells. Toxic agent, serine protease BLTX, in the venom produced by two distinct species, the North American short-tailed shrew (Blarina brevicauda) and the Mexican beaded lizard, undergo convergent evolution. Although their structures are similar, it turns out that they increased the enzyme activity and toxicity through different way of structure changes. These changes are not found in the other non-venomous reptiles or mammals. Another toxin BgK, a K+ channel-blocking toxin from the sea anemone Bunodosoma granulifera and scorpions adopt distinct scaffolds and unrelated structures, however, they have similar functions.
== Production == That Awkward Moment was developed by What If It Barks Films and was originally titled Are We Officially Dating?, the title it was released under in New Zealand, Indonesia, and Australia. The script was featured as one of the top comedy screenplays in the 2010 Hollywood Black List of best un-produced screenplays. In September 2013, the film's title changed to That Awkward Moment. Zac Efron was the first cast member to be announced in August 2012, alongside an announcement that production would begin in New York City in November 2012. Miles Teller was reported to have joined the cast in October 2012, with Imogen Poots and Michael B. Jordan following in November 2012.
Sources: en.wikipedia.org
Mercapturic acids are condensation products formed from the coupling of cysteine with aromatic compounds. They are formed as conjugates in the liver and are excreted in the urine. Mercapturic acids are formed as part of xenobiotic metabolism. A glutathione S-transferase first conjugates the foreign compound to glutathione, forming an adduct. The adduct is then converted to the mercapturic acid: the γ-glutamate and glycine residues in the glutathione molecule are removed by gamma-glutamyl transpeptidase and dipeptidases. In the final step, the cystine residue in the conjugate is acetylated. The mercapturic acid is then excreted. Levels of mercapturic acids in urine may be used as an indicator of exposure to, e.g., ethylene dibromide, acrylamide, and terbuthylazine.
In the United States, the Food and Drug Administration (FDA) is responsible for creating guidelines for the approval and use of drugs. The FDA requires that all approved drugs fulfill two requirements:
== Research == Researchers have explored the potential of teicoplanin as an antiviral agent against various viruses, including SARS-CoV-2. Laboratory studies indicate that teicoplanin inhibits cathepsin L, a host cell protease utilized by SARS-CoV-2 for cell entry via the endocytic pathway. In vitro experiments have demonstrated teicoplanin's ability to reduce SARS-CoV-2 infection, with reported IC50 values in the low micromolar range. This suggests potential efficacy against various SARS-CoV-2 variants due to conserved cathepsin L cleavage sites on the SARS-CoV-2 spike protein. Animal studies have also shown a protective effect against SARS-CoV-2 infection with teicoplanin pre-treatment.
Because the plant has not been well-studied in high-quality clinical research, little is known about its toxicology, adverse effects, or safety over long-term consumption. Its chief active psychoactive constituent is a structurally unique diterpenoid called salvinorin A, a potent κ-opioid agonist. Although not thoroughly assessed, preliminary research indicates S. divinorum may have low toxicity (high LD50). Its effects are rapid but short-lived.
An artificial organ is an engineered device that can be extra corporeal or implanted to support impaired or failing organ systems. Bioartificial organs are typically created with the intent to restore critical biological functions like in the replacement of diseased hearts and lungs, or provide drastic quality of life improvements like in the use of engineered skin on burn victims. While some examples of bioartificial organs are still in the research stage of development due to the limitations involved with creating functional organs, others are currently being used in clinical settings experimentally and commercially.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.